Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

National Trends in Cardiovascular Disease Medication Dispensing Patterns During the COVID-19 Pandemic: Insights From the Department of Veterans Affairs.

The American journal of cardiology·2026
Same author

Advancing in-hospital mortality prediction for acute myocardial infarction: An analysis from the American Heart Association Get With The Guidelines-Coronary Artery Disease Registry.

American heart journal·2026
Same author

The Challenge of Generative Artificial Intelligence for Journals.

The Canadian journal of hospital pharmacy·2026
Same author

The Canadian journal of hospital pharmacy·2026
Same author

Outcomes of individual DOACs vs. VKAs in AF patients with frailty: a systematic review and meta-analysis.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2026
Same author

Comparing Guidelines for Atrial Fibrillation: Focus on Emergency Medicine.

Annals of emergency medicine·2026
Same journal

Point-of-Care Polymerase Chain Reaction Testing for Respiratory Viruses Among Nursing Home Residents to Reduce Hospital Transfers.

JAMA internal medicine·2026
Same journal

Potential Biases in Assessment of Smallest Worthwhile Difference for Statin Therapy.

JAMA internal medicine·2026
Same journal

Error in Table 1.

JAMA internal medicine·2026
Same journal

Expansion of Civil Commitment for Substance Use Disorders-Not the Type of Commitment Our Patients Need.

JAMA internal medicine·2026
Same journal

Respiratory Outbreak Mitigation With Point-of-Care Testing in Long-Term Care: A Randomized Clinical Trial.

JAMA internal medicine·2026
Same journal

Potential Biases in Assessment of Smallest Worthwhile Difference for Statin Therapy-Reply.

JAMA internal medicine·2026
See all related articles

Related Experiment Video

Updated: May 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

When choosing statin therapy: the case for generics.

Jonas B Green1, Joseph S Ross, Cynthia A Jackevicius

  • 1Cedars-Sinai Medicine, Department of Medicine, Cedars-Sinai Health System, Los Angeles, CA 90049, USA. Jonas.Green@cshs.org

JAMA Internal Medicine
|January 11, 2013
PubMed
Summary
This summary is machine-generated.

Generic statins are the cost-effective choice for lowering cardiovascular risk in patients with dyslipidemia. This review supports the use of generic statins for initiating therapy to reduce cardiovascular risk.

Related Experiment Videos

Last Updated: May 15, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Pharmacoeconomics

Background:

  • Physicians benefit from reminders about cost-effective optimal care.
  • Generic statins offer a cost-effective option for cardiovascular risk reduction.

Purpose of the Study:

  • To review evidence supporting the use of generic statins for dyslipidemic patients.
  • To emphasize the role of generic statins in cardiovascular risk reduction.

Main Methods:

  • Literature review of evidence supporting generic statin use.
  • Analysis of cost-effectiveness in cardiovascular risk reduction.

Main Results:

  • Generic statins are the appropriate choice for initiating statin therapy in dyslipidemic patients.
  • Evidence supports the efficacy and cost-effectiveness of generic statins.

Conclusions:

  • Generic statins are a key component of cost-effective cardiovascular risk reduction.
  • Physicians should consider generic statins for patients initiating therapy.